Literature DB >> 28376159

Burdensome Research Procedures in Trials: Why Less Is More.

Jonathan Kimmelman1, David B Resnik2, Jeffrey Peppercorn3, Mark J Ratain4.   

Abstract

A large volume of trials involve invasive, nontherapeutic research procedures, like organ biopsy or sham surgeries, that can pose risks comparable with the experimental treatment itself but that have no direct benefit for volunteers. Though such procedures can enhance the value of clinical investigations, recent studies suggest that many studies involving invasive, nontherapeutic research procedures are not well planned and reported; some studies suggest that their results are often not utilized in the planning of new investigations. This commentary offers recommendations for how investigators, sponsors, and ethics committees might improve evaluation and implementation of studies involving invasive nontherapeutic procedures. We conclude by urging more demanding scientific standards for the rationale, design, and reporting of burdensome, nontherapeutic research procedures-particularly where they involve risk of serious complications.
© The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28376159      PMCID: PMC5756064          DOI: 10.1093/jnci/djw315

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  21 in total

1.  Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials.

Authors:  Randy F Sweis; Michael W Drazer; Mark J Ratain
Journal:  J Clin Oncol       Date:  2015-12-14       Impact factor: 44.544

2.  Safety and acceptability of the research lumbar puncture.

Authors:  Elaine R Peskind; Robert Riekse; Joseph F Quinn; Jeffrey Kaye; Christopher M Clark; Martin R Farlow; Charles Decarli; Charles Chabal; Darcy Vavrek; Murray A Raskind; Douglas Galasko
Journal:  Alzheimer Dis Assoc Disord       Date:  2005 Oct-Dec       Impact factor: 2.703

Review 3.  Trends in the use and role of biomarkers in phase I oncology trials.

Authors:  Bernardo H L Goulart; Jeffrey W Clark; Homer H Pien; Thomas G Roberts; Stan N Finkelstein; Bruce A Chabner
Journal:  Clin Cancer Res       Date:  2007-11-15       Impact factor: 12.531

4.  Rationale and design for PACE: patients with intermittent claudication injected with ALDH bright cells.

Authors:  Emerson C Perin; Michael Murphy; John P Cooke; Lem Moyé; Timothy D Henry; Judy Bettencourt; Amir Gahremanpour; Nicholas Leeper; R David Anderson; William R Hiatt; Joao A Lima; Bharath Venkatesh; Shelly L Sayre; Rachel W Vojvodic; Doris A Taylor; Ray F Ebert; Alan T Hirsch
Journal:  Am Heart J       Date:  2014-07-30       Impact factor: 4.749

5.  Patients' perceptions of research biopsies in phase I oncology trials.

Authors:  Charlotte Lemech; Divyanshu Dua; Joshua Newmark; Matilde Saggese; Emily Simmons; Paulina Spiliopoulou; Hendrik-Tobias Arkenau
Journal:  Oncology       Date:  2014-10-14       Impact factor: 2.935

6.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Authors:  Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

7.  Use of research biopsies in clinical trials: are risks and benefits adequately discussed?

Authors:  Michael J Overman; Janhavi Modak; Scott Kopetz; Ravi Murthy; James C Yao; Marshall E Hicks; James L Abbruzzese; Alda L Tam
Journal:  J Clin Oncol       Date:  2012-11-05       Impact factor: 44.544

8.  A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy.

Authors:  Enriqueta Felip; Federico Rojo; Martin Reck; Astrid Heller; Barbara Klughammer; Gemma Sala; Susana Cedres; Sergio Peralta; Heiko Maacke; Dorothee Foernzler; Marta Parera; Joachim Möcks; Cristina Saura; Ulrich Gatzemeier; José Baselga
Journal:  Clin Cancer Res       Date:  2008-06-15       Impact factor: 12.531

Review 9.  Trends in the characteristics, dose-limiting toxicities and efficacy of phase I oncology trials: The Cancer Research UK experience.

Authors:  Han Hsi Wong; Claire Barton; Gary Acton; Robert McLeod; Sarah Halford
Journal:  Eur J Cancer       Date:  2016-08-08       Impact factor: 9.162

10.  Reporting practices of pharmacodynamic studies involving invasive research procedures in cancer trials.

Authors:  G A Freeman; J Kimmelman; J Dancey; J G Monzon
Journal:  Br J Cancer       Date:  2013-07-25       Impact factor: 7.640

View more
  10 in total

1.  Tissue Acquisition in Clinical Trials-Essential for Progress.

Authors:  S Percy Ivy; Jeffrey S Abrams
Journal:  J Natl Cancer Inst       Date:  2017-04-01       Impact factor: 13.506

2.  Implications of Research Biopsies in Clinical Trials.

Authors:  Sarah M Dermody; Andrew G Shuman
Journal:  Oncologist       Date:  2021-08-31

3.  Understanding factors contributing to participant satisfaction in stroke walking recovery clinical trials.

Authors:  Mark Cummings; Sonia Pradhan; Sangeetha Madhavan
Journal:  Contemp Clin Trials Commun       Date:  2022-06-11

4.  Therapeutic Misconception about Research Procedures: Does a Simple Information Chart Improve Understanding?

Authors:  Gavin Campbell; Margie D Dixon; Minisha Lohani; John Cook; Rachel Hianik; Mary Catherine Thomson; Eli Abernethy; Colleen Lewis; Jeffrey Switchenko; R Donald Harvey; Rebecca D Pentz
Journal:  Ethics Hum Res       Date:  2022-03

5.  Biomarkers in early-phase trials: fundamental issues.

Authors:  Laura M Yee; Tracy G Lively; Lisa M McShane
Journal:  Bioanalysis       Date:  2018-06-20       Impact factor: 2.695

6.  Patient perspectives on window of opportunity clinical trials in early-stage breast cancer.

Authors:  George W Sledge; Jennifer L Caswell-Jin; Divya A Parikh; Lisa Kody; Susie Brain; Diane Heditsian; Vivian Lee; Christina Curtis; Mardi R Karin; Irene L Wapnir; Manali I Patel
Journal:  Breast Cancer Res Treat       Date:  2022-05-11       Impact factor: 4.624

7.  Umbrella and basket trials in oncology: ethical challenges.

Authors:  Karolina Strzebonska; Marcin Waligora
Journal:  BMC Med Ethics       Date:  2019-08-23       Impact factor: 2.652

8.  Details of risk-benefit communication in informed consent documents for phase I/II trials.

Authors:  Hannes Kahrass; Sabine Bossert; Christopher Schürmann; Daniel Strech
Journal:  Clin Trials       Date:  2020-11-24       Impact factor: 2.486

9.  Practical consideration for successful sequential tumor biopsies in first-in-human trials.

Authors:  Takafumi Koyama; Toshio Shimizu; Jun Sato; Yuki Katsuya; Satoru Iwasa; Shunsuke Kondo; Tatsuya Yoshida; Kazuki Sudo; Makoto Nishino; Yuichi Takiguchi; Kan Yonemori; Noboru Yamamoto
Journal:  Invest New Drugs       Date:  2022-04-11       Impact factor: 3.651

10.  The research burden of randomized controlled trial participation: a systematic thematic synthesis of qualitative evidence.

Authors:  Nivantha Naidoo; Van Thu Nguyen; Philippe Ravaud; Bridget Young; Philippe Amiel; Daniel Schanté; Mike Clarke; Isabelle Boutron
Journal:  BMC Med       Date:  2020-01-20       Impact factor: 8.775

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.